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Abstract Niemann^Pick type C disease (NPC) is a neurovis-
ceral (or, extremely rarely, only visceral) lipidosis caused by
mutations in the NPC1 gene or, in a few patients, the HE1
gene, which encode sterol regulating proteins. NPC is charac-
terised by a complex lipid anomaly including a disturbed cellular
tra⁄cking of cholesterol but also multi-lipid storage in visceral
organs and brain. Lipids were studied using conventional meth-
ods in enlarged spleens that had been removed from ¢ve patients
for di¡erent therapeutic and diagnostic reasons and found to
have microscopic signs of lysosomal storage disease not sus-
pected clinically. The spleen lipid ¢ndings with a concurrent
accumulation of cholesterol, sphingomyelin and glucosylcer-
amide (Acc-CSG) allowed us to suggest NPC diagnoses for
these patients, who were free of neurologic symptoms. From
two patients no material for con¢rmatory studies was available,
but in two other patients NPC diagnoses could be con¢rmed
with the ¢lipin cytochemical cholesterol assay and NPC1 gene
analysis, respectively. However, these tests and also HE1 gene
analysis were negative in a third patient. Since the Acc-CSG
lipid pattern seems to indicate a multi-lipid tra⁄cking defect
rather than being highly speci¢c for NPC, this patient, if not
a¡ected with very atypical NPC, may be a candidate for a
di¡erent lipid tra⁄cking disorder. The Acc-CSG pattern was
considered to be similar to the lipid pattern known for the lipid
rafts, these functional cell structures being probably disorgan-
ised and accumulated in late endosomes and lysosomes of NPC
cells.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Genetic defects in the sterol regulating proteins NPC1 and,
very rarely, HE1 (=NPC2) cause a fatal lipid storage disease,
Niemann^Pick type C disease (NPC) [1^3]. A well known
aspect of the complex lipid anomaly in NPC is the lysosomal
accumulation of cholesterol in cells (e.g. ¢broblasts) that are
cultured from typically a¡ected patients, challenged with
exogenous low density lipoprotein (LDL) cholesterol and an-
alysed using the cholesterol reagent ¢lipin [4,5]. This in vitro
e¡ect seems to re£ect the disturbed mobilisation, partitioning
and recycling (brie£y: tra⁄cking) of cholesterol considered as
an essential pathogenetic factor in NPC [6].
However, in visceral tissues (e.g. spleen) from NPC patients
accumulations of sphingolipids such as sphingomyelin and
glycolipids are concurrent to the increase in cholesterol
[1,7,8], while in brain tissue distinct cholesterol and sphingo-
myelin increases are absent but accumulations of glycolipids
including gangliosides are present [9]. It has been assumed
that not only the tra⁄cking of cholesterol but also that of
other lipids is disturbed in NPC, but the exact mechanisms
of such a multi-lipid tra⁄cking defect are not well understood
[10].
In recent studies the organisation of so-called lipid rafts,
which are functional lipid microdomains enriched in choles-
terol [11], sphingomyelin [12] and glycolipids [13] in lateral cell
regions, was suggested to be impaired in NPC [14]. The dis-
turbed lipid cycling in NPC cells seems to prevent the forma-
tion of cholesterol microdomains equivalent to rafts in the cell
periphery [15] but, instead, lead to overcrowding of lipid
structures in late endocytic organelles including lysosomes,
and lipid storage in NPC cells could result from falsely par-
titioned, lysosomally sequestered raft material [14,16].
Interestingly, the lipid pattern in raft microdomains [11^13]
is similar to that found in visceral, in particular splenic NPC
tissue [7] and the sphingolipids stored in NPC contain a high
percentage of saturated fatty acyl chains [17], tight packing of
such chains favouring raft formation [11,18]. Therefore, the
possibility was considered that the NPC spleen lipid pattern
with a concurrent accumulation of cholesterol, sphingomyelin,
glucosylceramide (Acc-CSG) and some other lipids [1,7,19]
re£ects a relatively unspeci¢c accumulation of normal lipid
membrane structures like the rafts, the Acc-CSG lipid pattern
suggesting a general a¡ection of lipid tra⁄cking involving
rafts.
We used conventional methods for lipid analysis of human
spleens, which were removed for di¡erent therapeutic and
diagnostic reasons, including the clari¢cation of splenome-
galy. We discovered the Acc-CSG lipid pattern in ¢ve patients
and suggested NPC diagnoses for these patients, who had a
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diagnosis of unclear lysosomal storage disease only on the
histopathology of their removed spleens, but were previously
undiagnosed and, in particular, always free of neurologic
symptoms. Since NPC usually presents as a neurovisceral lip-
idosis with severe neurodegeneration, non-neurologic [20,21]
or otherwise atypical NPC patients [1] may often remain un-
diagnosed.
There was consent only from three patients to con¢rmatory
studies for the suggested NPC diagnosis, which in fact could
be corroborated in two of them by NPC1 gene analysis and
cytochemical ¢lipin testing, respectively. However, in the third
patient, these tests and also HE1 gene analysis were negative,
raising the question whether the ¢nding of splenic Acc-CSG
may also have a potential in identifying candidates for lipid
tra⁄cking disorders possibly di¡erent from NPC.
2. Materials and methods
2.1. Tissue materials and patients
Formalin-¢xed splenic tissues from di¡erent patients with lipidoses
were collected in our diagnostic laboratory in Tu«bingen, Germany.
Clinical information on the patients being the subject of this study is
provided in Table 1. These patients felt well or complained of fatigue.
The reasons for admission were splenic rupture in an accident in
patient no. 1, unclear fever periods after a stay in India in patient
no. 2 and splenomegaly in patients 3^5. Splenomegaly in patients
1 and 2 was noted only after admission. The spleen volumes were
found to be increased by about 30% to about 400% over its normal
size corrected for age. In patients 3^5 there was an inhomogeneous
structure of the sonographed spleens with highly echogenic, up to 5 cm
large, round foci [22]. These lesions were the reason for splenectomy
in order to exclude malignant tissue transformation. The ¢rst suspi-
cion of a lysosomal storage disease, in particular lipidosis, came from
the histologic ¢ndings of foamy or sea-blue storage macrophages in
the spleen, or bone marrow cytologic ¢ndings of Niemann^Pick cells
or sea-blue histiocytes.
2.2. Cell culture and cytochemical testing for cholesterol accumulation
(¢lipin method)
Before use, the skin ¢broblast cultures from patients were main-
tained for 1 week in standard medium 199 (C.C. Pro GmbH, Neu-
stadt, Germany) with glutamine and 10% (v/v) foetal calf serum under
an atmosphere of 5% CO2. Lysosomal cholesterol present after chal-
lenging the cells with exogenously added LDL was analysed using a
described £uorescence microscopic method with the cholesterol re-
agent ¢lipin [5].
2.3. Lipid determination
Formalin-¢xed splenic tissue samples were available (see Section
2.3.1). Tissue was homogenised in 50 volumes of chloroform/methanol
(2/1, by vol.) and stirred for 1 h. Centrifuged supernatant (total lipid
extract) was analysed by thin-layer chromatography (TLC) as de-
scribed [8] with the following modi¢cations. For the determination
of sphingomyelin and glucosylceramide, amounts corresponding to
1^3 mg tissue wet weight were applied to start positions on thin-layer
plates (Merck, Darmstadt, Germany, no. 1.05721., activated for
10 min at 60‡C) as 15 mm streaks. Test amounts of standard cell
total lipid extract were also applied. The standard extract had been
calibrated in comparison with lipid standards (cholesterol, no. C8667,
Sigma, Deisenhofen, Germany; sphingomyelin from bovine brain, no.
4700, Roth, Karlsruhe, Germany; glucosylceramide, prepared in our
laboratory by preparative TLC from Gaucher disease spleen; ceram-
ides, natural mixture, no. 22100, Applied Science Lab., State College,
PA, USA). Chromatographic solvent systems were chloroform/meth-
anol/water (14/6/1, by vol., solvent A) and n-heptane/ethyl ether/conc.
acetic acid (80/6/1, by vol., solvent B). Plates were chromatographed
in solvent A, 16 cm upwards from start, dried and then chromato-
graphed in solvent B, 19 cm upwards from start. The dried plates were
stained by spraying with conc. acetic acid/conc. sulphuric acid/4-me-
thoxybenzaldehyde (490/10/3, by vol.) and heating (25 min, 140‡C).
After 1 day equilibration in the dark, lipid spot re£ectometric densi-T
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tometry was carried out at 600 nm (Fig. 1). Some precautions [23] and
lipid identity criteria [8] were carefully observed. Scanned lipid peak
areas were quanti¢ed in comparison with peak areas from the stan-
dard extract. Since in these chromatograms, cholesterol peaks were
too high and too close to the front for precise evaluation, and cer-
amide peaks were not separated, cholesterol and ceramide were quan-
ti¢ed on separate TLC plates. In the method described for cholesterol
[24], lipid extract from 0.3^0.9 mg tissue wet weight, and in the meth-
od for ceramide [25], extract from 4^8 mg wet weight, was used, as a
starting sample. The ceramide determination included three instead of
two [25] main ceramide fractions, the third fraction having distinctly
lower mobility on TLC (see component N in chromatogram of used
ceramide standard as depicted in an earlier paper [26]) than the other
fractions.
2.3.1. Assay of chemical resistance of cholesterol, sphingomyelin,
glucosylceramide and ceramide against formalin. Deep-frozen native
spleen tissue (0.1 g) from a juvenile NPC patient was homogenised in
1.33 mol/l aqueous formaldehyde solution (5 ml). From this homog-
enate, 1 ml was immediately dried and lipid-extracted (extract A) and
1 ml was incubated in a sealed vial for 2 weeks at 37‡C, dried and
extracted (extract B). Determination of lipids in extracts A and B was
according to Section 2.3.
3. Results
3.1. Cytochemical ¢ndings
Fibroblast cultures were available from patients nos. 2, 3
and 5 (Table 1). In the used cholesterol assay with ¢lipin, cells
from patients 3 (Fig. 1) and 5 were positive, with distinct
amounts of cholesterol-positive, £uorescent perinuclear lyso-
somal granules (Fig. 1) in at least three of ¢ve experiments,
but cells from patient no. 2 remained negative in six experi-
ments.
3.2. Biochemical ¢ndings in spleen samples
In Fig. 2 the lipid pattern with Acc-CSG in spleen tissue is
shown for patient no. 2 in comparison with a control. These
lipids have long been accepted in the literature as being resis-
tant against formalin [19,27,28], and the present experiment of
long-term incubation of homogenised tissue with formalin
(Section 2.3.1) resulted in quantitatively unchanged cholester-
ol, sphingomyelin, glucosylceramide and also ceramide in the
extracts (data not shown); some small di¡erences are ex-
plained by the methodological variability (see Table 2). The
Acc-CSG is the essential part of the known lipid changes in
NPC spleen [7] and was determined quantitatively in the
present ¢ve patients, where also the concentration of ceramide
was measured. The results (Table 2) show very similar Acc-
CSG, but normal or only very slightly higher than normal
ceramide content in the spleens of these patients, in compar-
ison with normal and pathologic controls. However, the
pathologic control with HE1 ( =NPC2) mutations had a dis-
tinct increase in the splenic ceramide concentration (Table 2).
Other lipids than those listed in Table 2 could not be studied
for their changes [1,7,19] because of their formalin sensitivity
(see also caption to Fig. 2).
3.2.1. Additional biochemical ¢ndings. In patients nos. 2, 3
and 5, Niemann^Pick disease type B and Gaucher disease, the
most important di¡erential diagnoses for adult lipidosis pa-
tients, were excluded by normal results of sphingomyelinase
and L-glucocerebrosidase activity assays [22] in ¢broblast
homogenates, using natural substrates, i.e. tritium-labelled
sphingomyelin and glucosylceramide, respectively. Compared
to the normal control range of sphingomyelinase activity (10^
40 nmol substrate cleaved per h and mg ¢broblast protein
[22]), patient no. 2Ps activity was slightly above the upper
control limit, no. 3Ps activity well within the control range,
but no. 5Ps activity very close to the lower control limit. Com-
pared to the normal control range of L-glucocerebrosidase
activity (0.3^0.8 nmol/h mg protein, low substrate concentra-
tion method, unpublished), the activities of patients 2, 3 and 5
were all well within this range. But also in patients 1 and 4,
where no appropriate enzyme test materials were available,
Niemann^Pick type B and Gaucher disease were almost com-
pletely excluded by the splenic Acc-CSG ¢nding, which lipid
pattern is well discriminated from the patterns in Niemann^
Pick B and Gaucher disease (Table 2).
3.3. Molecular ¢ndings
Molecular ¢ndings in patient no. 5 were published earlier
a b c
Fig. 1. Cytochemical assay of cholesterol with the ¢lipin method [5] in skin ¢broblast cultures. Cholesterol accumulation is seen by brightly
£uorescent cellular regions surrounding the £uorescence-negative areas of the cell nuclei. a: Early-infantile Niemann^Pick type C (NPC1 mu-
tated; unpublished) disease. b: Present patient no. 3 (Tables 1 and 2). c: Normal control proband (48 years old). Magni¢cation: U65.
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(see [21] for family no. 24) and included homozygous NPC1
mutations in the cysteine-rich lumenal loop of the NPC1 pro-
tein. Other molecular ¢ndings referred to in this study came
from generous personal communications for the present study
by Marie T. Vanier, Laboratoire Fondation Gillet-Me¤rrieux,
Centre Hospitalier Lyon-Sud, Pierre Be¤nite, France. Starting
from ¢broblast cultures of patient no. 2, no mutations were
found in the NPC1, nor in the HE1 gene, but it was emphas-
ised that the, though extended, NPC1 analysis may still have
missed peculiar NPC1 alterations. In the cells of patient no. 3,
one presumably pathogenic mutation on one NPC1 allele was
determined, and no HE1 mutation was found (unpublished).
4. Discussion
Although the lipid abnormalities present in NPC visceral
tissue, in particular spleen, have long been known [1,7,8],
they were not strictly considered in the not well elucidated
scenario of disturbed lipid tra⁄cking in NPC. The Acc-CSG
pattern as the major part of the NPC spleen lipid changes has
thus far been observed only in this disease and never corre-
lated with other lipid disorders. In fact, the Acc-CSG pattern
may be relatively unspeci¢c in a sense that it merely indicates
a general disorganisation of cellular lipids in which the accu-
mulation of cholesterol, sphingomyelin and glycolipids may
re£ect increased amounts of normal membrane compartments
which at their own have similarly high contents in those lipids.
Examples of such compartments are the lipid rafts (see Sec-
tion 1). It should be mentioned that the lipid composition of
rafts may not be very constant in di¡erent cells, but a tight
assembly of cholesterol and sphingolipids containing satu-
rated acyl chains [18] seems to be essential for these structures,
the sphingolipids probably varying in their sphingomyelin
[12], neutral and acidic glycosphingolipid patterns [11]. This
variability may give rise, for example, to rafts with high cho-
lesterol, sphingomyelin and glucosylceramide content in NPC
visceral tissue, but also rafts with high ganglioside content in
NPC brain. Rafts seem to have roles in cell signalling [12] and
serve as platforms for protein and lipid sorting and tra⁄cking
processes [11,14,29]. It is remarkable that a fraction of murine
NPC1 protein colocalises with rafts [30]. NPC1 protein being
defective in most human NPC cases [1,21], it is tempting to
propose a raft disorganisation that compromises signalling
and other functions in NPC cells. The involvement in cell
signalling and the high sphingolipid content of rafts have
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Fig. 2. Densitometric scans of total lipid extracts from formalin-
¢xed spleen corresponding to 1.4 mg tissue wet weight (‘Patient no.
2’, 26-year-old, see Tables 1 and 2) or 2.4 mg wet weight (‘Normal’,
29-year-old control proband), chromatographically separated and
stained on a silicagel thin-layer plate. Abscissa, distance from chro-
matographic start (‘St’) position; ordinate, linear for absorption at
600 nm, a 0.1 absorption unit is marked. ‘SF’, solvent front. Peak
identi¢cation (some lipids have two chemical subtypes, i.e. two
peaks): C, cholesterol; G, glucosylceramide; L, lactosylceramide;
P, phospholipids and formalin-induced products; S, sphingomyelin;
U, unidenti¢ed. Seen are increased cholesterol, glucosylceramide and
sphingomyelin peaks in patient no. 2 as compared to normal con-
trol (note di¡erent wet weight equivalents). C, G and S are resistant
against formalin (see Section 3); also, L is formalin-resistant, but
only L is additionally and arti¢cially released by formalin action
from gangliosides (unpublished).
Table 2
Lipids in formalin-¢xed spleen (values as Wg/mg tissue wet weight)
Total lipids Cholesterol Sphingomyelin Glucosylceramide Ceramide
Normal controls (n=5; 2-, 8-, 29-, 48- and 56-year-old), range 19^25 1.9^2.9 1.1^2.0 0.05^0.10 0.2^0.45
Methodological variation coe⁄cient (%) 9 12 12.5 20.5 22.5
Present patients (see Table 1)
no. 1 45 7.7 6.2 1.0 0.45
no. 2 44 9.2 4.8 1.1 0.5
no. 3 50 10.5 8.8 1.0 0.3
no. 4 51 9.7 7.7 0.9 0.45
no. 5a 48 9.0 6.6 1.4 0.5
Late-infantile neurologic NPCb 60 11.9 10.3 2.5 0.6
Early-infantile NPC with HE1 ( =NPC2) mutationsc 46 11.0 9.9 0.85 0.95
Niemann^Pick disease type B (30-year-old) 55 5.5 21.5 0.05 0.25
Gaucher disease type 1 (22-year-old) 79 1.4 1.4 37 0.4
aHomozygous NPC1 mutations (see ref. [21] for family no. 24).
bPublished earlier [8] and re-studied.
cHomozygous HE1 mutations (see ref. [31] for Case 4) in an earlier published patient [32].
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also suggested a role of free ceramide [11,12], and experimen-
tal raft models can be stabilised by an increased ceramide
proportion, although natural rafts usually seem to be free of
high ceramide proportions [11]. We were still interested
whether the Acc-CSG lipid pattern as a putative sign of raft
accumulation in NPC spleen was associated with an increase
in ceramide, but analysis of ceramide on TLC revealed normal
or only very slightly elevated ceramide levels in the present
¢ve patients. However, the pathologic control of the HE1
(NPC2) mutated, early-infantile patient had an about three-
fold elevated concentration in all ceramide fractions studied
(see Section 2). The present quantitative data show about
twice higher control spleen ceramide concentrations than re-
ported in the literature [28], which may be due to methodo-
logical di¡erences.
In the present study the demonstration of the Acc-CSG
pattern in visceral patient tissue was supposed to identify
patients with NPC or similar lipid tra⁄cking disorders. In
fact, patients with previously undiagnosed NPC were identi-
¢ed. The Acc-CSG pattern was also equally present in NPC
patients of both the NPC1 and HE1 gene mutated type
[19,31,32] (Table 2). However, one Acc-CSG-positive patient
(no. 2 in Table 1) but with negative NPC1 and HE1 molecular
results and also negative cholesterol cytochemistry using ¢li-
pin was provisionally diagnosed as having a very atypical
NPC condition or other lipid tra⁄cking disorder.
A clinical aspect of the present study was that of providing
some information on the very rare variant of non-neurologic
NPC disease [20,21]. The fatal downhill course in most NPC
patients is dominated by progressive neurodegeneration,
where muscle weakness, ataxia, epilepsy and dementia are
some frequent features [1]. However, the present patients, in-
cluding those with a con¢rmed NPC diagnosis, have remained
free of neurologic symptoms; no. 3 (Table 1) is working as
usual, taking responsibility in a penal institution, and he re-
cently had an unremarkable magnet resonance neuro-imaging
examination; no. 5 seemed to be slightly simply structured
psychically but is a friendly and active lady, fully able to
take care of herself [21]. These two patients would not have
been diagnosed as having NPC, unless their splenic Acc-CSG
lipid pattern had been shown. Screening for Acc-CSG can
also be done in routinely formalin-¢xed spleen. Enlarged
spleens present in very di¡erent diseases but including a num-
ber of lysosomal storage disorders are sometimes removed for
therapeutic or diagnostic reasons.
In conclusion, the Acc-CSG lipid pattern identi¢ed in
pathologic spleen tissue is of diagnostic use, but, in addition,
it might have a potential in identifying candidates for lipid
tra⁄cking disorders similar to, or possibly di¡erent from
NPC. The Acc-CSG pattern might also be viewed as a sign
of a peculiar pathology of the lipid rafts in these disorders.
The present lipid study using conventional methods was
thought to stimulate investigations on the mechanisms of pu-
tative lipid tra⁄cking disorders in selected patients.
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